Back to Search
ANDRIA MILLER, LPC
LPC
Addiction (Substance Use Disorder) Counselor
NPI: 1457502486IndividualAccepts Medicare
Specialties, Licenses & Credentials
Mental Health Counselor
Counselor — Mental Health
Code: 101YM0800X
294347-6004(UT)
Addiction (Substance Use Disorder) CounselorPrimary
Counselor — Addiction (Substance Use Disorder)
Code: 101YA0400X
C2537(OR)
Education
OTHER
Class of 2005
Clinical Trials (4)
4
Linked Trials
0
Recruiting
4
With Results
A Study of Infliximab for Treatment Resistant Major Depression
NCT00463580COMPLETEDPHASE4PRINCIPAL_INVESTIGATOR
Bupropion Versus Escitalopram on Reward Circuitry and Motivational Deficits
NCT04352101COMPLETEDPHASE4PRINCIPAL_INVESTIGATOR
Effects of Riluzole on CNS Glutamate and Fatigue in Breast Cancer Survivors With High Inflammation
NCT02796755COMPLETEDPHASE4PRINCIPAL_INVESTIGATOR
Effectiveness of Escitalopram in Preventing or Reducing Depressive Symptoms in People Receiving Interleukin-2 Treatment
NCT00352885COMPLETEDPHASE4STUDY_CHAIR
Research & Publications (6)
Antidepressants for the treatment of depression in people with cancer.
PMID 36999619·Cochrane Database Syst Rev·2023
6-review
Inhibition of tumor necrosis factor improves sleep continuity in patients with treatment resistant depression and high inflammation.
PMID 25529904·Brain Behav Immun·2015
2-rct
The impact of escitalopram on IL-2-induced neuroendocrine, immune, and behavioral changes in patients with malignant melanoma: preliminary findings.
PMID 23575741·Neuropsychopharmacology·2013
2-rct
A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers.
PMID 22945416·JAMA Psychiatry·2013
4-observational
Transcriptional signatures related to glucose and lipid metabolism predict treatment response to the tumor necrosis factor antagonist infliximab in patients with treatment-resistant depression.
PMID 23624296·Brain Behav Immun·2013
2-rct
Neurobehavioral effects of interferon-α in patients with hepatitis-C: symptom dimensions and responsiveness to paroxetine.
PMID 22353759·Neuropsychopharmacology·2012
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 2 locations total
- Address
- 1200 HILYARD ST STE 570
EUGENE, OR 97401 - Phone
- (458) 205-7070
Quick Facts
- NPI
- 1457502486
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 2
- Years in Practice
- 21
- Clinical Trials
- 4
- Publications
- 6
Are you this provider?
Claim Your Profile